KdT Ventures Secures $100M Fourth Fund to Fuel Early-Stage Biotech Startups

Fund Size:
KdT Ventures has raised a $100 million fourth fund to invest in early-stage frontier science companies, particularly those combining technology with biology.

Investment Focus:
The fund will focus on backing startups in the life sciences sector, including gene therapy and genomics companies.

Previous Investments:
KdT Ventures has previously invested in companies such as Rejuvenate Bio (gene therapy developer) and 54gene (Africa-focused genomics company).

Fund Announcement:
The fourth fund was announced on October 16, 2024, and is oversubscribed, indicating strong interest from investors.

Investment Strategy:
KdT Ventures aims to support early-stage startups that are pioneering new technologies in the life sciences field, leveraging its expertise to help these companies grow and succeed.